Method for determining rivaroxaban and related substances thereof
A technology of related substances and determination methods, applied in the field of medicinal chemical analysis, can solve the problems of poor separation of impurity peaks and impurity peaks near the main peak, and achieve the effects of good column efficiency, reduced baseline interference, and improved time efficiency.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0055] The method for separating and measuring rivaroxaban and its impurities specifically includes the following contents:
[0056] 1) Instruments and conditions
[0057] Instrument: high performance liquid chromatography; chromatographic column: core-shell chromatographic column with octadecylsilane bonded silica gel as filler, model is Agilent Poroshell 120EC-C18, 150×4.6mm, 2.7μm or equivalent Chromatographic column; detector detection wavelength: 250nm; mobile phase flow rate: 1.2ml / min; mobile phase A: with 10mmol / mL potassium dihydrogen phosphate buffer solution (1.36g potassium dihydrogen phosphate adds water 1000ml, adds 200 μ l phosphoric acid)-methanol ( 95:5) is mobile phase A; mobile phase B: acetonitrile-methanol-water (50:30:20) is mobile phase B; diluent: acetonitrile-water (70:30); column temperature is 50 ° C; The elution gradient is shown in Table 2 below:
[0058]
[0059] Table 2
[0060] Injection volume: 5 μl.
[0061] 2) Experimental steps
[00...
Embodiment 2
[0072] 1) on the basis of embodiment 1, adjust the flow rate to be 1.0ml / min
[0073] 2) The experimental results are shown in Table 4 below:
[0074]
[0075]
[0076] Table 4
[0077] Result: Baseline separation can be achieved between each component, which meets the separation requirements of the Pharmacopoeia, and the blank solvent does not interfere with the detection of each component (such as Figure 5-6 and Table 4).
Embodiment 3
[0079] 1) on the basis of embodiment 1, adjust the flow rate to be 1.4ml / min
[0080] 2) The experimental results are shown in Table 5 below:
[0081]
[0082] table 5
[0083] Results: The baseline separation of each component can be achieved, which meets the separation requirements of the Pharmacopoeia, and the blank solvent does not interfere with the detection of each component. (Such as Figure 7-8 and shown in Table 5).
PUM
Property | Measurement | Unit |
---|---|---|
Concentration | aaaaa | aaaaa |
Wavelength | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com